Díaz CA, Zottis GC, da Acunha MLV, Verissimo DC, Rehder R, Biurrum BLA

Language: Spanish
References: 12
Page: 363-367
PDF size: 966.19 Kb.

ABSTRACT

High-grade gliomas have been known among adult population, especially during the fourth and seventh decade of life, differently from the pediatric population. In contrast to adults, high-grade gliomas are significantly less common than low-grade lesions, consisting of a consensus matter over the clinical manifestations, therapy, and follow up. In the pediatric population, high-grade lesions characterized a discrete prevalence in males (1.7:1 e 3:2). Tumor localization out of the cerebral hemispheres in the adult population is exception, in contrast to children pattern which consists of a diffuse pattern. The most common sites to present with expressive lesion consists of frontal lobe (27%) and brainstem (25%). A number of cytogenetic and molecular factors have been associated with outcome, especially p53 protein, presented in 75% immunohistochemical evaluations, related to 6-7 months of survival. Tumor complete resection should be associated as part of the treatment, especially in hemispheric lesions located in regions considered not eloquent. The correlation of the extension of the resection and the period free from the disease consist of important factors to be considered in case of aggressive reintervention. Surgical treatment associated to radiotherapy and chemotherapy provides 11-33 months of survival. The present case report describes male patient, 5 years old, diagnosed with high-grade glioma located in frontotemporoparietal left lobe, submitted to surgical and chemotherapy and radiotherapy.

REFERENCES

1. Kramer S, Meadows AT, Jarrett P, et al: Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst 1983; 70: 49-55.

2. Buetow PC, Smirniotopoulos JG, Done S: Congenital brain tumors: a review of 45 cases. AJR 1990; 155: 587–93.

3. Jellinger K, Sunder-Plassmann M. Congenital intracranial tumors. Neuropaediatrie 1973; 4: 46-63.

4. Watanable K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secundary glioblastomas. Brain Pathol 1996; 6: 217-24.

5. Litofsky NS, Hinton D, Raff el C. The lack of a role for p53 in astrocytoma in pediatric patients. J Neurosurg 1994; 34: 967-73.

6. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997; 57: 304-9.

7. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas. Cancer Res 2001; 61: 7404-7.

8. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry VRK. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 2005; 41: 292-9.

9. Suri V, Das P, Jain A, Sharma MC, Borkar SA, Suri A, et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 2009; 11: 274-80.

10. Kin AE, Memet O. Congenital glioblastoma multiforme; case report and review of the literatura. J Neurosurg (6 Suppl Pediatrics) 2006: 105: 473-9.

11. Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, et al. Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 2010; 6: 145-9.

12. Sánchez-Herrera F, Castro-Sierra E, Gordillo-Domínguez LF, Vaca-Ruiz MA, Santana-Montero B, Perezpeña-Diazconti M Glioblastoma multiforme in children: experience at Hospital Infantil de Mexico Federico Gomez. Childs Nerv Syst 2009; 25: 551-7.